Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders.
C J Smith; E K Perry; R H Perry; J M Candy; M Johnson; J R Bonham; D J Dick; A Fairbairn; G Blessed; N J Birdsall (Profiled Authors: Perry, Elaine K; Perry, Robert H)
Department of Neuropathology Research, Newcastle General Hospital, Newcastle upon Tyne, U.K.
Journal of neurochemistry 1988;50(3):847-56.
Total muscarinic receptor levels, the levels of the subtypes exhibiting high and low affinity for pirenzepine, and the high- and low-affinity agonist states of the receptor were investigated in hippocampal tissue obtained at autopsy from mentally normal individuals and the following pathological groups: Alzheimer's disease, Parkinson's disease, Down's syndrome, alcoholic dementia, Huntington's chorea, and motor-neurone disease. A moderate decrease in the density of both high-affinity pirenzepine and high-affinity agonist subtypes was found in Alzheimer's disease, whereas a trend towards an increase in the overall muscarinic receptor density was apparent in the parkinsonian patients without dementia, mainly due to an increase in the low-affinity agonist state; the differences between the Alzheimer's disease and nondemented parkinsonian cases were highly significant. As previously reported, the levels of both choline acetyltransferase and acetylcholinesterase were markedly reduced in both Alzheimer's disease and Parkinson's disease--with a greater loss of both enzymes in the demented subgroup of parkinsonian patients. Activities of the cholinergic enzymes were also extensively reduced in Down's syndrome, accompanied by a loss of high-affinity pirenzepine binding. There were no significant receptor or enzyme alterations in the other groups studied. These observations suggest that in the human brain, extensive degeneration of cholinergic axons to the hippocampus, as indicated by a loss of cholinergic enzymes, is not necessarily accompanied by extensive muscarinic receptor abnormalities (as might be expected if a major subpopulation were presynaptic). Moreover, the opposite changes in muscarinic binding in Parkinson's and Alzheimer's diseases may be related to the greater severity of dementia in the latter disease.
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Grants
-
1.
SELKOE, DENNIS J
AGING IN THE BRAIN--ROLE OF THE FIBROUS PROTEINS
1 August 1978 - 30 April 1985
NATIONAL INSTITUTE ON AGING
Total Funding: $ 614,195
-
2.
DAVIES, PETER
AGING AND DEMENTIA--CHOLINERGIC NEURON BIOCHEMISTRY
1 April 1979 - 31 March 1983
NATIONAL INSTITUTE ON AGING
Total Funding: $ 444,743
-
3.
Thal, Leon J
GENE THERAPY OF BASAL FOREBRAIN CHOLINERGIC LESIONS
1 September 2000 - 31 August 2006
NATIONAL INSTITUTE ON AGING
Total Funding: $ 1,415,081
Related Publications
-
1.
1986A B Norman; S N Blaker; L Thal; I Creese
Neuroscience letters 1986;70(2):289-94. -
2.
1995M Vestling; R F Cowburn; N Venizelos; L Lannfelt; B Winblad; A Adem
Journal of neural transmission. Parkinson's disease and dementia section 1995;10(1):1-10. -
3.
1997J A Court; S Lloyd; M Johnson; M Griffiths; N J Birdsall; M A Piggott; A E Oakley; P G Ince; E K Perry; R H Perry
Brain research. Developmental brain research 1997;101(1-2):93-105.

Appears in this Publication









